A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia in Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures

This is a global, multicenter, randomized, double-blind, placebo-controlled study using recombinant human thrombopoietin stimulating factor ( rhTPO) to treat adults with Chronic liver disease-related thrombocytopenia (CLDT). The study will evaluate rhTPO efficacy in elevating platelet level and its safety in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce pre-procedural platelet transfusion needs and the requirements for rescue treatment for bleeding.

Start Date20 Oct 2026

Sponsor / Collaborator-

ChiCTR2600131329

/ SuspendedNot ApplicableIIT

A Study on the Efficacy and Safety of rhTPO in the Treatment and Prevention of CTIT in Children with Solid Tumors

Start Date01 Sep 2026

Sponsor / Collaborator

West China Second University Hospital

ChiCTR2600130622

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Recombinant Human Thrombopoietin for Prevention and Treatment of Antibody-Drug Conjugate-Induced Thrombocytopenia in Solid Tumors

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

100 Translational Medicine associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

100 Patents (Medical) associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

255

Literatures (Medical) associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

01 Nov 2026·BURNS

Experimental study on the treatment of mouse burn injury combined with smoke inhalation injury using thrombopoietin

Article

Author: Liu, Tian ; Duan, Hongjie ; Wei, Minghui ; Deng, Zhaoyang ; Hu, Fangchao ; Qu, Yirui ; Zhou, Hui ; Lei, Baisheng ; Chi, Yunfei ; Liu, Xiangyu

BACKGROUND:

Burn injuries complicated by smoke inhalation significantly increase clinical severity and can lead to acute respiratory distress syndrome (ARDS). Inhalation injury is predominantly caused by exposure to toxic combustion gases, with thermal damage from steam being relatively uncommon. Thrombocytopenia is frequently observed in severe burns and is associated with poor outcomes, whereas platelet transfusion can carry clinically important risks. Recombinant human thrombopoietin (rhTPO), a hematopoietic growth factor used clinically for thrombocytopenia, may represent an alternative strategy for improving platelet-related recovery after burn-associated inhalation injury.

METHODS:

Female C57BL/6 mice were subjected to a 30% total body surface area (TBSA) full-thickness burn combined with smoke inhalation injury. Mice were randomized into three groups: injury-only control, rhTPO subcutaneous injection group (SIG), and rhTPO nebulized inhalation group (NIG). Treatments commenced 0.5 h post-injury and continued for 3 days. Outcomes included 120-hour survival, arterial blood gas parameters, platelet count, thromboelastography, lung histopathology scores, plethysmography-based pulmonary function, and lung cytokine profiles.

RESULTS:

Both rhTPO administration routes improved 120-hour survival, increased platelet counts, and improved selected thromboelastography parameters. H&E-based histological assessment showed lower lung injury scores at later time points, and plethysmography-based respiratory parameters improved by 120 h. IL-1β and TNF-α levels were lower in rhTPO-treated groups, whereas IL-6 did not show a consistent decrease and should be interpreted cautiously.

CONCLUSIONS:

rhTPO administration, via either systemic or inhaled route, improved survival and several physiological and histological outcomes in this murine model of burn with smoke inhalation injury. Because this study did not include a healthy/sham control group or direct assays of platelet activation, pulmonary microthrombi, or rhTPO pharmacokinetics, the findings should be interpreted as evidence of therapeutic association rather than proof of a defined anti-inflammatory mechanism beyond the measured platelet-related changes.

01 Oct 2026·AMERICAN JOURNAL OF HEMATOLOGY

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

Article

Author: Zhou, Yongjian ; Nan, Yuemin ; Tan, Youwen ; Shang, Jia ; Chen, Yu ; Chen, Shiyan ; Han, Yifan ; Han, Tao ; Xin, Yongning ; Xu, Jinghang ; Zhang, Liaoyun ; Zhou, Zhongyin ; Zeng, Zhan ; Chen, Jun ; Luo, Xinhua ; Shan, Yunfeng ; Lin, Ning ; Wang, Kai ; Wu, Hong ; Xu, Xiaoyuan ; Ding, Huiguo ; Yu, Yanyan ; Wang, Sikui ; Li, Rongkuan ; Liu, Zhen ; Lu, Mingqin ; Sheng, Jifang ; Yang, Li ; Kang, Yi ; Guan, Yujuan ; Yu, Zujiang ; Jin, Jinglan ; Yang, Jinhui ; Lu, Zheng ; Hou, Jinlin ; Zhang, Dazhi ; Liu, Pingguo ; Xie, Wen ; An, Ping ; Wen, Zhili ; Huang, Yan ; Xiong, Qingfang ; Lin, Kecan ; Wang, Wei ; Li, Jiaping ; Shi, Rongshu

ABSTRACT:

Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive procedures. In this multicenter, randomized (2:1), double‐blind, placebo‐controlled phase III trial, 120 adult Chinese patients with CLD‐related thrombocytopenia (platelet count < 50 × 10 9 /L) received rhTPO ( n = 80) or placebo ( n = 40) once daily for up to 5 or 7 days. The primary endpoint was the proportion of patients with sustained platelet counts ≥ 50 × 10 9 /L from 24 h before invasive procedure to 7 days post‐procedure, without requiring emergency bleeding management. The primary endpoint was achieved by 85.0% of patients in the rhTPO group versus 12.5% in the placebo group ( p < 0.0001). Preoperatively, platelet counts ≥ 50 × 10 9 /L were achieved in 92.5% and 20.0% of patients in the rhTPO and placebo groups, respectively ( p < 0.0001). Platelet transfusion was avoided in 92.5% of rhTPO‐treated patients versus 25.0% of placebo‐treated patients ( p < 0.0001). The median duration of platelet counts ≥ 50 × 10 9 /L was significantly longer with rhTPO than with placebo (21.0 vs. 3.0 days, p = 0.0007). Treatment‐related treatment‐emergent adverse events (TEAEs) occurred in 12.5% of patients in both the rhTPO and placebo groups. No treatment‐related serious adverse events were reported. Overall, rhTPO was effective and well tolerated in patients with CLD‐related thrombocytopenia and may represent a viable therapeutic option for those undergoing elective invasive procedures. Trial Registration:www.chinadrugtrials.org.cn : number CTR20230919.

01 Sep 2026·INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial

Article

Author: Li, Hongmei ; Zhang, Zhiye ; Zhang, Xiaozhi ; Hua, Ying ; Ji, Yongling ; Liang, Zhaohui ; Ma, Xuezhen ; Man, Li ; Wang, Chaojie ; Zhao, Fen ; Meng, Xianyu ; Chen, Jianbing ; Wang, Jun ; Wang, Linlin ; Wang, Jin ; Yu, Jinming ; Chen, Jun ; Wang, Shijiang

PURPOSE:

Concurrent chemoradiation therapy is the standard therapy for limited-stage small cell lung cancer (LS-SCLC) but induces cancer therapy-induced thrombocytopenia (CTIT), which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin (rhTPO) in preventing CTIT in this patient population.

METHODS AND MATERIALS:

This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cisplatin or carboplatin chemotherapy with concurrent radiation therapy were given subcutaneous rhTPO (300 IU/kg/d) on days 1-5, 8-12, and 15-19 during radiation therapy. rhTPO treatment was stopped if platelet count reached ≥300 × 10⁹/L or increased by ≥100 × 10⁹/L from baseline. Primary endpoints were the nadir and peak platelet count.

RESULTS:

From March 8, 2024, to October 10, 2024, 56 LS-SCLC patients were enrolled. During the rhTPO treatment period, nadir platelet count (×10⁹/L) was 128.54 ± 54.15, and peak platelet count reached 409.23 ± 173.50. Overall incidence of CTIT was 33.9% (19/56), including 8.9% (5/56) grade 3, and no grade 4-5 events. A total of 78.9% of patients (15/19) experienced platelet count recovery to ≥100 × 10⁹/L during the rhTPO treatment period. Median time for platelet count recovery from <100 × 10⁹/L to ≥100 × 10⁹/L was 8 days (95% CI, 6-14). Multivariable logistic regression analysis revealed that low baseline platelet count (<150 × 10⁹/L) was an independent risk factor for developing CTIT (odds ratio, 4.26; 95% CI, 1.08-16.78; P = .038). No patients required platelet transfusions or experienced radiation therapy interruptions, and only one patient required a reduction in the dose of chemotherapy throughout the entire study. Moreover, no serious adverse events were reported. rhTPO-related adverse reactions were infrequent and predominantly grade 1 (eg, transient platelet elevation).

CONCLUSIONS:

Prophylactic rhTPO during concurrent chemoradiation therapy for patients with LS-SCLC demonstrated a potential benefit in maintaining platelet counts with a low incidence of CTIT. These findings support further investigation of rhTPO as a preventive strategy for high risk CTIT patients.

News (Medical) associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

22 Mar 2023

·www.biospace.com

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HONG KONG, March 21, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achieved blistering performance, and contract development and manufacturing organization (CDMO) business demonstrated big potential. New drugs started to embrace a commercialization wave, and license-out and license-in partnerships geared up. Revenue in 2022 increased by 7.5% year on year to approximately RMB 6.90billion. Gross profit rose 7.5% year on year to approximately RMB 5.67 billion. The normalized earnings before interest, taxes, depreciation and amortization (EBITDA) were approximately RMB2.80 billion, an increase of 27.7% over the same period last year. The normalized net profit attributable to owners of the parents was approximately RMB2.16 billion, a rise of 25.2% over the same period last year. The solid performance growth supported a sustainable dividend policy. According to the resolution of the board of directors, 3SBio will pay a dividend of HKD0.1. This year marked the 30th anniversary of 3SBio. On top of steady financial performance growth, the Company has been delivering on its corporate social responsibility and constantly improving environmental, social and governance (ESG) management. In 2022, 3SBio improved from A to AA on the MSCI ESG rating, surpassing 88% of the world's biotechnology companies. In the future, 3SBio will further expand its advantages as an integrated platform for research and development (R&D), manufacturing, commercialization and external partnerships, and consolidate and enhance its status as a leading biopharmaceutical company. Core biopharmaceutical products posted robust performance In 2022, the Company's core products (TPIAO, Yisaipu, EPIAO/SEPO, Mandi) maintained their leadership in the Chinese market, and Cipterbin saw a significant rise in its sales. According to IQVIA data, sales of TPIAO, the world's only commercial recombinant human thrombopoietin (rhTPO) used to treat thrombocytopenia, totaled RMB 3.40 billion in 2022, a year-on-year increase of 10.3%. In 2022, TPIAO achieved a renewal in the National Reimbursement Drug List (NRDL) and it was listed with the highest-level recommendation by the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the Diagnosis and Treatment of Cancer Therapy Induced Thrombocytopenia (CTIT) (2022 Edition). As the leaders in the recombinant human erythropoietin (rhEPO) market for 20 years, EPIAO and SEPO maintained their leading position, with sales of RMB 1.13 billion in 2022, maintaining a dominant market share of 44.5%. Sales of Yisaipu for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis were RMB 512 million. Its safety and efficacy have been verified in the Chinese market for 18 years. Compared with developed countries in Europe and the United States, the penetration rate of biologic anti-rheumatic drugs in China's mainland is still low, and the product has broad growth potential in the future. Sales of Cipterbin for the treatment of HER2-positive metastatic breast cancer were RMB 159 million, an increase of 138.1% year on year, and the number of hospitals and patients covered had a significant rise compared with 2021. In 2022, Cipterbin was successfully renewed in the NRDL and the reimbursement restrictions for its use in combination with vinorelbine were abolished. The CSCO Clinical Guidelines for the Diagnosis and Treatment of Breast Cancer (2022 Edition) listed Cipterbin with the highest-level Class I recommendation for the treatment of patients with HER2-positive advanced breast cancer. Hair health business achieved blistering growth The Company's hair health business achieved blistering growth. Sales of the key product Mandi (minoxidil tincture) were RMB 891 million in 2022, representing a year-on-year increase of 48.1%. Sales through retail pharmacies soared 65% year on year, and sales through e-commerce channels jumped 58% year on year, maintaining strong growth momentum and driving up the penetration rate of the Mandi brand. As an effective hair growth therapy, Mandi (5% minoxidil) has been granted the highest-level recommendation in the Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia in Chinese Population and the Chinese Expert Consensus on the Diagnosis and Treatment of Androgenetic Alopecia in Women (2022 Edition). 3SBio is committed to enhancing customer education regarding the use of Mandi for individuals experiencing hair loss, as well as improving the application cycles of the drug in the treatment of hair loss. In the future, the educational campaign will help improve the penetration rate of this product and thus further expand its market share. CDMO business demonstrated big potential The Company's CDMO business made significant progress. In 2022, 3SBio completed a total of RMB 166 million worth of CDMO customer orders, marking a year-on-year increase of 49.6%, which demonstrated remarkable results in the first year of operation. The CDMO business has secured customer orders valued at more than RMB 100 million, including partnerships with leading Chinese and overseas pharmaceutical companies and biotech companies, and its services cover all aspects ranging from pre-clinical to commercialization. 3SBio's CDMO business has multiple competitive advantages, including the technological advantages associated with engaging in the whole process spanning from R&D to production of biopharmaceutical products over the years; the scalable cost advantages of a single 10,000-litre bioreactor for commercial production; the production cost advantages brought by the capability to manufacture raw materials such as culture medium and chromatography filling . 3SBio will focus on providing proprietary and cost-effective biological CDMO services, in a bid to help customers accelerate the launch of high-quality new drugs, and expand its own CDMO business. New drugs embraced a commercialization boom under robust pipelines In 2022, 3SBio posted a total R&D cost of approximately RMB 693 million. There were 31 product candidates within the active pipeline, with 26 being developed as innovative drugs. Among them, there were 7 product candidates in oncology, 13 product candidates that target auto-immune and other diseases, 9 product candidates in nephrology; and 2 product candidates in dermatology. Among them, the pipeline in the field of auto-immune diseases, which includes anti-IL-4Rα antibody, anti-IL-5 antibody, anti-IL-1β antibody and anti-IL-17A antibody, was among the leading pack in clinical research progress in China. The Company's pipeline includes a number of upcoming blockbuster products. Among them, the new drug applications (NDAs) on new formulations or indications of three core products have been accepted. The anti-TNF α pre-filled aqueous injection solution of Yisaipu (301S) will address limitations of the powder injection, and will significantly improve the treatment compliance among hundreds of thousands of medical professionals and patients. Minoxidil foam(MN709) is the only one of its kind domestically, adding a medication choice for hair loss patients with sensitive scalp. The phase III clinical trial of TPIAO for pediatric immune thrombocytopenia (ITP) met the preset primary endpoint, and it is expected to meet the treatment needs of children with ITP. In addition, the candidates acquired via external partnerships also achieved big progress. The NDA application of nalfurafine hydrochloride (TRK820) for the treatment of refractory pruritus in patients undergoing maintenance hemodialysis has been accepted, which is expected to fill the treatment gap for dialysis pruritus in China and bring significant clinical benefits to millions of patients with nephrology and liver diseases. 3SBio will continue to focus on four fields of its strength, namely, nephrology, autoimmune diseases, hair and skin, and oncology, and accelerate the candidates that lead in R&D progress in China. The Company will fast-track the auto-immune products with R&D progress surpassing domestic peers;and supercharge the bridging clinical trials for Clascoterone cream in acne indication and Remitch in liver diseases pruritus, both with vast market potentials and targeting an extraordinary number of patients.. Eight new products are expected to be launched in 2023, and the Company will submit NDAs for more than 10 products in the next three years, ushering in a boom in new drug launches. License-out and license-in partnerships geared up In 2022, 3SBio continued to accelerate external partnerships by licensing in high-quality products and licensing out its own products. For example, the Company entered into a licensing agreement with Syncromune Inc, a bio-pharmaceutical company headquartered in the U.S., to develop and commercialize the Company's anti-programmed cell death protein 1 (PD1) mAb (609A) for use with Syncrovax™ immuno-oncology combination therapy worldwide. The Company signed a licensing cooperation agreement with Chengdu Kelingyuan Pharmaceutical Technology Co Ltd to grant the worldwide development and commercialization rights of Cipterbin antibody sequence for antibody-drug conjugate (ADC) to Kelingyuan. The Company also entered into a cooperation agreement with Cosmo Pharmaceuticals N.V. to obtain exclusive right to develop and commercialize Winlevi®, the world's first marketed topical androgen receptor inhibitor to treat acne under its subsidiary Cassiopea, in Greater China. In the future, 3SBio will continue to selectively seek M&A and cooperation opportunities to enrich its portfolio and prepare for future growth. Dr. Jing LOU, Chairman and CEO of 3SBio, commented: "Since its establishment 30 years ago, 3SBio has consistently improved its financial performance and advanced new drug research and development. This has led to robust momentum in its four business segments, empowering the Company's sustainable development. Moving forward, 3SBio is committed to sharpening its focus on refined management and ensuring the healthy development of all business lines. The company will continue to dedicate significant efforts towards the delivery of new drug discoveries. Furthermore, 3SBio is fully committed to its social responsibilities, and is determined to benefit more patients with its high-quality and high-standard drugs." About 3SBio Inc. 3SBio is a leading bio-pharmaceutical company integrating research and development (R&D), manufacturing and commercialization, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Company owns more than 100 national invention patents and has launched more than 30 products into the market, covering several therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology and dermatology. The Company owns four R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. The Company has a pipeline of 31 products under R&D, and 26 of them are the national new drugs. The Group also owns five production bases complying with the GMP standards. In the future, 3SBio will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to foster a world-leading biopharmaceutical company in China. Please visit for additional information. Cautionary Note and Forward-Looking Statements This press release contains forward-looking statements, such as those relating to business or products outlook, or Company's intent, plans, beliefs, expectation and strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realized in the future. With respect to any new product or new indication, we cannot guarantee that we will be able to successfully develop or eventually launch and market such product or indication. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding such risks and uncertainties may be found in our other public disclosure documents. The scientific information involved may only be preliminary and empirical. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. View original content to download multimedia: SOURCE 3SBio Company Codes: HongKong:1530

License out/inPhase 3Clinical ResultFinancial Statement

22 Jun 2015

·www.fiercebiotech.com

3SBio Acquires Global Rights to Anti-TNF mAb

SHENYANG, China, June 22, 2015 -- 3SBio Inc., (HKEX: 1530) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired theChina rights from Apexigen in 2006. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical testing and demonstrated higher potency than the best-known available TNF inhibitors, including adalimumab and infliximab, potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory diseases. In March 2015, 3SBio initiated a dose-escalating Phase I trial for SSS07 in China (NCT02460393). A Phase 1b trial is also scheduled to start in early 2016 using multiple doses in healthy individuals. "Dosing of the first cohort of Phase I trial participants with SSS07 was a significant milestone towards our goal of introducing a safe, effective and affordable treatment for the estimated 17 million patients globally who suffer from rheumatoid arthritis, including 4.5 to 5.0 million in China", commented Dr. Jing Lou, 3SBio's Chairman and CEO, "Acquiring the global rights to this anti-TNF mAb technology also positions 3SBio to participate in the US$35 billion global market for anti-TNF inhibitors." About Anti-TNF mAb/SSS07 Anti-TNF mAb/SSS07 is a genetically engineered monoclonal antibody that inhibits TNF. TNF is one of the key chemokine messengers that regulate the inflammatory process and plays an important role in the underlying mechanisms of conditions such as rheumatoid arthritis, psoriasis, and many other inflammatory disorders. When human body produces too much TNF, it overwhelms the immune system's ability to control inflammation of the joints or of psoriasis-affected skin areas. The TNF inhibitors are molecules that disrupt the TNF function. Such blockage has been shown to result in a significant reduction in inflammatory activity and reduce symptoms, inhibit the progression of structural damage, and improve physical function in patients with moderate to severe rheumatoid arthritis. Several TNF inhibitors developed by other companies have been approved by the US FDA and the Chinese FDA. SSS07's pre-clinical testing showed higher potency than the best-known available products, including adalimumab and infliximab, potentially improving treatment options for rheumatoid arthritis patients. The prevalence of rheumatoid arthritis in China is approximately 0.32% to 0.36%, or 4.5 million to 5.0 million patients. The number of rheumatoid arthritis patients in China is expected to increase with an aging population and increasing urbanization, presenting favorable market potential. According to IMS, the TNF inhibitor market in China reached RMB708 million in 2013. The Global Burden of Disease 2010 study estimated that the global prevalence of rheumatoid arthritis was 0.24%. About 3SBio Inc. 3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide. Pipeline candidates include SSS07, an anti-TNF monoclonal antibody with a Phase I trial underway in China for the treatment of rheumatoid arthritis; NuPIAO/SSS06, a long-acting erythropoiesis-stimulating agent (ESA) for anemia associated with renal failure or chemotherapy and peri-operative blood cell mobilization which has entered into Phase I clinical trials in China; Uricase PEG-20/SSS11, a modified pegylated recombinant uricase from Candida utilis for the treatment of refractory gout and tumor lysis syndrome which has completed US Phase I trials; Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for treating acute leukemia; and Tanibirumab/SSS23, an anti-VEGFR2 monoclonal antibody for treating solid tumors. A new state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards. 3SBio is China's leading specialist in nephrology and oncology supportive care with more than 700 sales and marketing professionals covering over 3,400 hospitals in key cities supported by a nationwide network of over 110 distributors and logistics providers. EPIAO has been the top selling rhEPO product in China since 2002 with a market share over 40%. 3SBio trades on the Stock Exchange of Hong Kong under code 1530. Please visit www.3sbio.com for additional information. About Apexigen Inc. Apexigen, based in San Carlos, California, is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and other life-threatening or debilitating diseases. Apexigen is advancing its lead immuno-oncology antibody (APX005M) in the clinical development. Using its robust technology platform, Apexigen has developed a pipeline of therapeutic candidates for cancer and inflammatory diseases and established seven corporate partnerships including strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover and develop first-in-class antibody therapeutics.

Phase 1Drug ApprovalImmunotherapy

100 Deals associated with Recombinant human thrombopoietin (Sunshine Pharmaceutical)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Recombinant human thrombopoietin (Sunshine Pharmaceutical)	L03AA	DB16364

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	01 Jan 2010
Thrombocytopenia	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	10 May 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic liver disease	Phase 3	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	18 May 2023
Acute Radiation Syndrome	Phase 2	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	08 Dec 2025
Liver Cirrhosis	Phase 1	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	28 Jun 2018
liver function failure	Phase 1	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	28 Jun 2018
Hepatic Insufficiency	Phase 1	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	11 Jun 2018
Bone marrow depression	IND Approval	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	06 Nov 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05411705 (CCORG-001, ESMO2026)	Phase 4	-	165	rhTPO + rhTPOancer therapy	jjaungtzaq(dmesqroxak) = ruhumdjlam bsjqiuttio (tpzutszhjj ) View more	Positive	23 Oct 2026
				anticancer therapy	jjaungtzaq(dmesqroxak) = ytkakbkofv bsjqiuttio (tpzutszhjj ) View more
ASCO2026	Not Applicable	Thrombocytopenia	456	rhTPO (Early intervention group 1 (platelets 75-<100×10^9/L))	niiefxrhou(pytogifhxs) = tewmffayic xygnhhtjph (snwsitcoiw ) View more	Positive	29 May 2026
				rhTPO (Early intervention group 2 (50-<75×10^9/L))	niiefxrhou(pytogifhxs) = rmnxepeqae xygnhhtjph (snwsitcoiw ) View more
EHA2026	Not Applicable	B-Cell Malignant Neoplasm	21	Recombinant Human Thrombopoietin (rhTPO) (B-cell malignancy + post-CAR-T thrombocytopenia)	fxoqeacvhd(lrzskojyza) = vwtuuqodrn klygtspcsa (hbfevefyrd, 30.25 - 156.50) View more	Positive	12 May 2026
NCT05583838 (TE-ITP, Pubmed \| EClinicalMedicine)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	157	Recombinant human thrombopoietin	tpetumvoej(wmehxceczh) = xpiaxqqatp ssrcbdewvd (thaeihgpjo ) View more	Positive	01 Sep 2025
				Eltrombopag	tpetumvoej(wmehxceczh) = pujgtejyht ssrcbdewvd (thaeihgpjo )
NCT05583838 (TE-ITP, EClinicalMedicine) Manual	Phase 4	Purpura, Thrombocytopenic, Idiopathic	157	Recombinant human thrombopoietin (rhTPO)	dbzkpunuqf(txvoqszxah) = xoebucgrwb nygswiewcs (hnjhaqsfxl, 6.0 - 7.0) View more	Positive	21 Aug 2025
				Eltrombopag	dbzkpunuqf(txvoqszxah) = owyrosedsa nygswiewcs (hnjhaqsfxl, 9.0 - 25.0) View more
ASH2024 Manual	Not Applicable	Anemia, Aplastic First line	39	recombinant human thrombopoietin+Hetrombopag+ IST	ikvzkkmfrr(smphgljanf) = hygfqcjhub jsbuvsiwog (jtknytgvvr ) View more	Positive	09 Dec 2024
PRNewswire Manual	Phase 3	Thrombocytopenia	-	特比澳	mwernovdsh(hepuanrsca) = pfhrwfpsnl wluuazjsmp (ltapobjckz, 75.26，92.00) Met	Positive	26 Jul 2024
				Placebo	mwernovdsh(hepuanrsca) = pcjkvizfib wluuazjsmp (ltapobjckz, 4.19，26.80) Met
CTR20230919 (NEWS)	-	Thrombocytopenia	-	重组人血小板生成素-特比澳	lpxzprwzsg(ffodgpcflu) = zqzehmlaxo qvnnrdgfby (maezjukalf )	Positive	26 Jul 2024
				安慰剂	lpxzprwzsg(ffodgpcflu) = txqflpyzxi qvnnrdgfby (maezjukalf )
EHA2024	Not Applicable	Anemia, Aplastic	17	rhTPO+HETROM+CsA	gxpdxozkcp(semqqdxwuk) = tyoakepyca sfzyrfteuv (lzfayxrcyp )	Positive	14 May 2024
				HETROM+CsA	gxpdxozkcp(semqqdxwuk) = qynhfugrtu sfzyrfteuv (lzfayxrcyp )
ISTH2021	Not Applicable	Purpura, Thrombocytopenic, Idiopathic Second line	96	rhTPO	gvgzjoojif(nhqvwvvkyz) = omfugopbqz psvcrrxkkt (oaklmknocz )	-	17 Jul 2021
				eltrombopag	gvgzjoojif(nhqvwvvkyz) = dhjckgyjaq psvcrrxkkt (oaklmknocz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis